GSK and CureVac to develop next generation mRNA COVID-19 vaccines
- Companies aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use
- Development to begin immediately targeting vaccine availability in 2022, subject to regulatory approval
- GSK will also support manufacture of up to 100 million doses of CureVac?s first generation COVID-19 vaccine CVnCoV in 2021